American Oriental Bioengineering (OTCMKTS:AOBI) is a Canada‐based life sciences company specializing in the development, manufacture and distribution of traditional Chinese medicine (TCM) products, dietary supplements, cosmeceuticals and health‐care formulations. The company integrates research and development, raw material extraction, quality control and finished‐goods manufacturing under its two state‐of‐the‐art facilities located in Guangdong and Sichuan provinces. Through a combination of in‐house brands and contract manufacturing services, AOBI addresses growing global demand for natural health solutions grounded in centuries of herbal medicine tradition.
The company’s core offerings include botanical extracts, nutritional capsules, liquid tonics and topical cosmeceuticals. Key product lines feature standardized formulations based on goji berry, ginseng, peony root and other well‐known herbs, along with collagen peptides and specialized skin‐care serums. AOBI maintains rigorous quality assurance processes, from raw‐herb sourcing and active ingredient purification to final product testing, enabling it to serve both retail consumers under its proprietary labels and third‐party clients seeking original equipment manufacturing (OEM) partnerships.
American Oriental Bioengineering distributes its products across mainland China, North America and Southeast Asia. In China, it leverages leading e‐commerce platforms and a network of pharmacies and wellness centers. In overseas markets, the company utilizes cross‐border online marketplaces and strategic distribution agreements to reach health‐food retailers, specialty clinics and consumer‐facing channels in the United States and Canada. This multi‐channel approach has helped AOBI build brand recognition among evolving demographics interested in holistic wellness.
Founded in the early 1990s with roots in traditional herbal extraction, the company expanded into international markets in the mid-2000s and began trading on the OTC market to support its global growth strategy. Today, AOBI is led by Chairman and CEO Haipeng Wang, who has more than two decades of experience in pharmaceutical R&D, and CFO Xiaojun Li, a financial executive with a track record in cross-border capital management. Under their guidance, the company continues to invest in research collaborations with academic institutions and pursue product innovation to address emerging health and beauty trends.
AI Generated. May Contain Errors.
Free AOBI Stock Alerts